Webinar 2: Initiating patients with GW CBD
Webinar 2: Managing adverse events and determining the optimal dose of GW CBD
Webinar 2: Initiating GW CBD in patients who have previously received a non-regulatory approved cannabis-based product
Webinar 2: Panel discussion and audience Q & A
Webinar 1: GW CBD patient profile
Webinar 1: Starting and maintaining patients on GW CBD and managing adverse events
Webinar 1: GW CBD in patients who have tried or are currently receiving non-regulatory approved cannabis-based products
Elizabeth Thiele provides an overview of the diverse patient profiles of individuals with epilepsy who may benefit from GW CBD treatment, and how to initiate and escalate dosing, and manage adverse events.
Please Select A Video:
Overview & Learning Objectives
Epidyolex® is indicated for use as adjunctive therapy of seizures associated with LGS or DS, in conjunction with clobazam, for patients 2 years of age and older.
Epidyolex® is indicated for use as adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC) for patients 2 years of age and older.
This session is organised and funded by GW Pharmaceuticals, Plc. and is intended for an HCP or prescriber audience only. The indication may differ in your country; please refer to local prescribing information.
After watching this touchMEETING HIGHLIGHTS, you should be able to:
- Describe some of the diverse profiles of patients who may benefit from cannabidiol
- Understand how to initiate GW CBD and reach optimal dosing
- Discuss potential strategies to manage patients experiencing adverse events (AEs)
- Understand how to manage patients with previous or current experience of non-regulatory approved cannabis-based products
Adverse events should be reported according to local regulations. For the UK, reporting forms and information can be found on the MHRA yellow card site as yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to GW pharma on firstname.lastname@example.org .
MHRA. Epidyolex Summary of product characteristics available at: mhraproducts10781.